GeneTex

  • Country / Location Selection

United States (US)

PD-L1 antibody

KO/KD Comparison Orthogonal Overexpression
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Anti-PD-L1 antibody used in Immunocytochemistry/ Immunofluorescence (ICC/IF). GTX104763
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Anti-PD-L1 antibody used in IHC (Paraffin sections) (IHC-P). GTX104763
Anti-PD-L1 antibody used in Immunocytochemistry/ Immunofluorescence (ICC/IF). GTX104763
Anti-PD-L1 antibody used in IHC (Paraffin sections) (IHC-P). GTX104763
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Anti-PD-L1 antibody used in IHC (Paraffin sections) (IHC-P). GTX104763
Anti-PD-L1 antibody used in IHC (Paraffin sections) (IHC-P). GTX104763
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763

Cat. No. GTX104763

Reference 37
10

Host

 Rabbit

Clonality

 Polyclonal

Isotype

 IgG

Application

 WB, ICC/IF, IHC-P, IHC-Fr, FACS

Reactivity

 Human
Package
100 μl ($399),
25 μl ($169)
See all PD-L1 products
PRODUCT

Summary

PD-L1 antibody recognizes programmed death-ligand 1 (PD-L1) protein, also known as B7 homolog 1 (B7-H1) and cluster of differentiation 274 (CD274) protein. PD-L1 is found on various cancer cells and transduces immunosuppressive signals by binding to the programmed cell death protein 1 (PD-1) on effector T cells, thereby diminishing immune system attacks on malignant cells. Blocking the interaction between PD-L1 and PD-1 with PD-L1 antibodies is generating great clinical interest as a mode of immunotherapy against a number of cancers.

APPLICATION

Application Note

*Optimal dilutions/concentrations should be determined by the researcher.
Application Recommended Dilution
WB 1:500-1:3000
ICC/IF 1:100-1:1000
IHC-P 1:100-1:1000
IHC-Fr Assay dependent
FACS Assay dependent
Not tested in other applications.

Calculated MW

33 kDa. ( Note )

Observed MW

50 kDa. The observed M.W. is based on the following publication. PMID: 23674495

Positive Control

MDA-MB-231 (24μg/ml Tunicamycin treatment for 16 hr) , MDA-MB-231 , A431(100 ng/mL IFN-gamma treatment for 48 hr)

PROPERTIES

Form

Liquid

Buffer

1XPBS, 1% BSA, 20% Glycerol (pH7)

Preservative

0.025% ProClin 300

Storage

Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.

Concentration

0.29 mg/ml (Please refer to the vial label for the specific concentration.)

Antigen Species

Human

Immunogen

Carrier-protein conjugated synthetic peptide encompassing a sequence within the C-terminus region of human PD-L1. The exact sequence is proprietary.

Purification

Purified by antigen-affinity chromatography.

Conjugation

Unconjugated

RRID

AB_1240586

Note

For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.

TARGET

Synonyms

CD274 molecule , B7-H , B7H1 , PD-L1 , PDCD1L1 , PDCD1LG1 , PDL1

Cellular Localization

Isoform 1: Cell membrane; Single-pass type I membrane protein , Isoform 2: Endomembrane system; Single-pass type I membrane protein

Background

Involved in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation and cytokine production.

Database

Research Area

DATA IMAGES

Anti-PD-L1 antibody used in Western Blot (WB). GTX104763

GTX104763 WB Image

KO/KD

Wild-type (WT) and PD-L1 knockout (KO) MDA-MB-231 cell extracts (30 μg) were separated by 10% SDS-PAGE, and the membrane was blotted with PD-L1 antibody (GTX104763) diluted at 1:4000. The HRP-conjugated anti-rabbit IgG antibody (GTX213110-01) was used to detect the primary antibody.

Anti-PD-L1 antibody used in Western Blot (WB). GTX104763

GTX104763 WB Image

Comparison Orthogonal

Untreated (–) and treated (+) A431 whole cell extracts (30 μg) were separated by 10% SDS-PAGE, and the membranes were blotted with PD-L1 antibody (GTX104763) diluted at 1:1200 and competitor's antibody (CST#13684) diluted at 1:500. The HRP-conjugated anti-rabbit IgG antibody (GTX213110-01) was used to detect the primary antibody.

*The competitor is not affiliated with GeneTex and does not endorse this product.

Anti-PD-L1 antibody used in Immunocytochemistry/ Immunofluorescence (ICC/IF). GTX104763

GTX104763 ICC/IF Image

KO/KD

PD-L1 antibody detects PD-L1 protein at cell membrane by immunofluorescent analysis.
Sample: MDA-MB-231 cells were fixed in ice-cold MeOH for 5 min.
Green: PD-L1 stained by PD-L1 antibody (GTX104763) diluted at 1:500.
Blue: Fluoroshield with DAPI (GTX30920).

Anti-PD-L1 antibody used in Western Blot (WB). GTX104763

GTX104763 WB Image

Various whole cell extracts (30 μg) were separated by 10% SDS-PAGE, and the membrane was blotted with PD-L1 antibody (GTX104763) diluted at 1:2000. The HRP-conjugated anti-rabbit IgG antibody (GTX213110-01) was used to detect the primary antibody, and the signal was developed with Trident ECL plus-Enhanced.

Anti-PD-L1 antibody used in Western Blot (WB). GTX104763

GTX104763 WB Image

Various whole cell extracts (30 μg) were separated by 10% SDS-PAGE, and the membrane was blotted with PD-L1 antibody (GTX104763) diluted at 1:2000. The HRP-conjugated anti-rabbit IgG antibody (GTX213110-01) was used to detect the primary antibody.

Anti-PD-L1 antibody used in Western Blot (WB). GTX104763

GTX104763 WB Image

KO/KD

Non-transfected (–) and transfected (+) A431 whole cell extracts (30 μg) were separated by 10% SDS-PAGE, and the membrane was blotted with PD-L1 antibody (GTX104763) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody (GTX213110-01) was used to detect the primary antibody.

Anti-PD-L1 antibody used in Western Blot (WB). GTX104763

GTX104763 WB Image

Overexpression

Various whole cell extracts were separated by 10% SDS-PAGE, and the membranes were blotted with PD-L1 antibody (GTX104763) diluted at 1:600 and with DDDDK tag antibody (GTX115043) diluted at 1:3000 to detect DDDDK-tagged PD-L2. The HRP-conjugated anti-rabbit IgG antibody (GTX213110-01) was used to detect the primary antibody.

Anti-PD-L1 antibody used in IHC (Paraffin sections) (IHC-P). GTX104763

GTX104763 IHC-P Image

PD-L1 antibody detects PD-L1 protein at cell membrane by immunohistochemical analysis.
Sample: Paraffin-embedded human ovarian cancer.
PD-L1 stained by PD-L1 antibody (GTX104763) diluted at 1:4000.
Antigen Retrieval: Citrate buffer, pH 6.0, 15 min

Anti-PD-L1 antibody used in Immunocytochemistry/ Immunofluorescence (ICC/IF). GTX104763

GTX104763 ICC/IF Image

PD-L1 antibody detects PD-L1 protein by immunofluorescent analysis.
Sample: MDA-MB-231 (left) and HeLa (right) cells were fixed in ice-cold MeOH for 5 min.
Green: PD-L1 stained by PD-L1 antibody (GTX104763) diluted at 1:500.
Blue: Hoechst 33342 staining.
Scale bar= 10 μm.

Anti-PD-L1 antibody used in IHC (Paraffin sections) (IHC-P). GTX104763

GTX104763 IHC-P Image

PD-L1 antibody detects PD-L1 proteinat cell membrane in human ovarian carcinoma by immunohistochemical analysis.
Sample: Paraffin-embedded human ovarian carcinoma.
PD-L1 antibody (GTX104763) diluted at 1:1000.

Antigen Retrieval: Citrate buffer, pH 6.0, 15 min

Anti-PD-L1 antibody used in Western Blot (WB). GTX104763

GTX104763 WB Image

Orthogonal

Untreated (–) and treated (+) MDA-MB-231 whole cell extracts (30 μg) were separated by 10% SDS-PAGE, and the membrane was blotted with PD-L1 antibody (GTX104763) diluted at 1:1000.

Anti-PD-L1 antibody used in Western Blot (WB). GTX104763

GTX104763 WB Image

Comparison

Various whole cell extracts (30 μg) were separated by 12% SDS-PAGE, and the membranes were blotted with PD-L1 antibody (GTX104763) diluted at 1:2000 and competitor's antibody (CST#13684) diluted by 1:500. The HRP-conjugated anti-rabbit IgG antibody (GTX213110-01) was used to detect the primary antibody.
*The competitor is not affiliated with GeneTex and does not endorse this product.

Anti-PD-L1 antibody used in IHC (Paraffin sections) (IHC-P). GTX104763

GTX104763 IHC-P Image

Comparison

PD-L1 antibody detects PD-L1 protein at cell membrane in PD-L1 protein-expressing cell lines by immunohistochemical analysis. Antibodies: PD-L1 antibody (GTX104763) diluted at 1:1000, and competitor's antibody diluted at 1:50. Samples: Negative (-), low positive (+), intermediate positive (++) and strong positive (+++) cell line cores assessed using Quantitative Digital Pathology.
Antigen Retrieval: Citrate buffer, pH 6.0, 15 min
*The competitor is not affiliated with GeneTex and does not endorse this product.

Anti-PD-L1 antibody used in IHC (Paraffin sections) (IHC-P). GTX104763

GTX104763 IHC-P Image

Comparison

PD-L1 antibody detects PD-L1 protein at cell membrane in human ovarian carcinoma by immunohistochemical analysis. Antibodies: PD-L1 antibody (GTX104763) diluted at 1:1000, and competitor's antibody diluted at 1:50.
Antigen Retrieval: Citrate buffer, pH 6.0, 15 min
*The competitor is not affiliated with GeneTex and does not endorse this product.

Anti-PD-L1 antibody used in Western Blot (WB). GTX104763

GTX104763 WB Image

Non-transfected (–) and transfected (+) 293T whole cell extracts (30 μg) were separated by 10% SDS-PAGE, and the membrane was blotted with PD-L1 antibody (GTX104763) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody (GTX213110-01) was used to detect the primary antibody, and the signal was developed with Trident ECL plus-Enhanced.

REFERENCE

Application Reference

Wu Y et al. Nat Cancer 2023; 4 (3) : 382-400 Disrupting the phase separation of KAT8-IRF1 diminishes PD-L1 expression and promotes antitumor immunity.
Application : IHC-P
Reactivity : Human
Chung SY et al. Neoplasia 2023; 35 : 100856 A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer.
Chung BS et al. Int J Mol Sci 2022; 23 (21) PD-L1 Expression in High-Risk Early-Stage Colorectal Cancer-Its Clinical and Biological Significance in Immune Microenvironment.
Su KW et al. Cells 2022; 11 (19) Thyroid Hormone Induces Oral Cancer Growth via the PD-L1-Dependent Signaling Pathway.
Application : WB, ICC/IF
Reactivity : Human
You-Zhe Lin et al. Comput Struct Biotechnol J 2022; 20 : 241-251 miR-4759 suppresses breast cancer through immune checkpoint blockade.
Application : WB
Reactivity : Human
Show More +
Submit a Reference

REVIEW

PD-L1 antibody Cat. No. GTX104763

Rating
( Average 4.8 based on 10 users reviews)
Application
Western Blot(WB)
( Average 4.8 based on 10 users reviews)
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Date : Anonymous submitted on 10-Aug-2021
Score :
Application Tested : WB
Sample Species : Hu
Figure Note : The data was peer reviewed and published in the journal Cancers (Basel) in 2019.PMID: 31835799
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Date : Anonymous submitted on 10-Aug-2021
Score :
Application Tested : WB
Sample Species : Hu
Figure Note : The data was peer reviewed and published in the journal Cancers (Basel) in 2019.PMID: 31835799
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Date : Anonymous submitted on 10-Aug-2021
Score :
Application Tested : WB
Sample Species : Hu
Figure Note : The data was peer reviewed and published in the journal Cancers (Basel) in 2019.PMID: 31835799
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Date : Anonymous submitted on 10-Aug-2021
Score :
Application Tested : WB
Sample Species : Hu
Figure Note : The data was peer reviewed and published in the journal Cancers (Basel) in 2019.PMID: 31835799
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Date : Anonymous submitted on 10-Aug-2021
Score :
Application Tested : WB
Sample Species : Hu
Figure Note : The data was peer reviewed and published in the journal Cancers (Basel) in 2019.PMID: 31905966
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Date : Anonymous submitted on 10-Aug-2021
Score :
Application Tested : WB
Sample Species : Hu
Figure Note : The data was peer reviewed and published in the journal Cancers (Basel) in 2019.PMID: 31905966
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Date : Anonymous submitted on 09-May-2021
Score :
Application Tested : WB
Sample Species : Hu
Sample : Huh7 cells
Amount used : 10 μg
Blocking : 5% skim milk in TBST, 27°C, 1Hr
Primary Antibody : 1:5000, 4°C, 12Hr
Secondary Antibody : GTX213110-01, 1:5000, 27°C, 2Hr
Lane Description : Two groups (regorafenib -/+) of whole cell extracts (10 μg) were separated by 12% SDS-PAGE, and the membrane was blotted with PD-L1 antibody (GTX104763) diluted at 1:5000. The HRP-conjugated anti-rabbit IgG antibody (GTX213110-01) was used to detect the primary antibody.
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Date : Anonymous submitted on 18-Mar-2021
Score :
Application Tested : WB
Sample Species : Hu
Figure Note : The data was peer reviewed and published in the journal Nat Commun in 2020. PMID: 32245950
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Date : Anonymous submitted on 18-Mar-2021
Score :
Application Tested : WB
Sample Species : Hu
Figure Note : The data was peer reviewed and published in the journal Nat Commun in 2020. PMID: 32245950
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Date : Anonymous submitted on 22-May-2017
Score :
Application Tested : WB
Sample Species : Hu
Sample : SK-LMS-1 cells
Amount used : 30 μg
Blocking : 3%BSA, 25°C, 0.5Hr
Primary Antibody : 1:1000, 4°C, 16Hr
Show More +
Submit a Review
Application Reference
Wu Y et al. Nat Cancer 2023; 4 (3):382-400 Disrupting the phase separation of KAT8-IRF1 diminishes PD-L1 expression and promotes antitumor immunity.
Application : IHC-P
Reactivity : Human
Chung SY et al. Neoplasia 2023; 35:100856 A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer.
Chung BS et al. Int J Mol Sci 2022; 23 (21) PD-L1 Expression in High-Risk Early-Stage Colorectal Cancer-Its Clinical and Biological Significance in Immune Microenvironment.
Su KW et al. Cells 2022; 11 (19) Thyroid Hormone Induces Oral Cancer Growth via the PD-L1-Dependent Signaling Pathway.
Application : WB, ICC/IF
Reactivity : Human
You-Zhe Lin et al. Comput Struct Biotechnol J 2022; 20:241-251 miR-4759 suppresses breast cancer through immune checkpoint blockade.
Application : WB
Reactivity : Human
Hung YH et al. Am J Cancer Res 2022; 12 (2):713-728 Semaphorin 4C promotes motility and immunosuppressive activity of cancer cells via CRMP3 and PD-L1.
Application : FACS
Reactivity : Human
Omenai SA et al. PLoS One 2022; 17 (2):e0263615 Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients.
Application : IHC-P
Reactivity : Human
Asrini R et al. Mol Clin Oncol 2022; 16 (2):42 Expression of programmed cell death ligand-1 protein in germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Application : IHC-P
Reactivity : Human
Lin YZ et al. Computational and Structural Biotechnology Journal 2022; 20:241-251 miR-4759 suppresses breast cancer through immune checkpoint blockade.
Application : WB
Reactivity : Human
Jesus Pacheco-Torres et al. Cancer Metab 2021; 9 (1):10 The PD-L1 metabolic interactome intersects with choline metabolism and inflammation.
Application : WB
Reactivity : Human
Li L et al. Pharmacological Research - Modern Chinese Medicine 2021; 1 A combination therapy of ingredients from TCM for the prevention and treatment of gastric cancer by targeting HER2/ PD-L1.
Li L et al. Cancer Sci 2021; 112 (5):1772-1784 Systematic insight into the active constituents and mechanism of Guiqi Baizhu for the treatment of gastric cancer.
Application : WB
Reactivity : Human
Tuminello S et al. Transl Lung Cancer Res 2020; 9 (4):1343-1360 PD-L1 as a prognostic biomarker in surgically resectable non-small cell lung cancer: a meta-analysis.
Qin G et al. Nat Commun 2020; 11 (1):1669 NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer.
Chou CW et al. Am J Cancer Res 2020; 10 (8):2621-2634 The stabilization of PD-L1 by the endoplasmic reticulum stress protein GRP78 in triple-negative breast cancer.
Application : WB
Reactivity : Human
Huang TY et al. Cells 2020; 9 (8) NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer.
Application : WB
Reactivity : Human
Kim D et al. J Clin Med 2020; 9 (5) Differential Expression and Clinicopathological Significance of HER2, Indoleamine 2,3-Dioxygenase and PD-L1 in Urothelial Carcinoma of the Bladder.
Application : IHC-P
Reactivity : Human
Lenouvel D et al. Oral Oncol 2020; 106:104722 Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: A systematic review and comprehensive meta-analysis.
Gondhowiardjo SA et al. PLoS One 2020; 15 (3):e0230449 Tumor microenvironment predicts local tumor extensiveness in PD-L1 positive nasopharyngeal cancer.
Application : IHC-P
Reactivity : Human
Nguyen HD et al. Cancers (Basel) 2019; 11 (12) The α9 Nicotinic Acetylcholine Receptor Mediates Nicotine-Induced PD-L1 Expression and Regulates Melanoma Cell Proliferation and Migration.
Pan MR et al. Cancers (Basel) 2019; 12 (1) Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer.
Application : WB
Reactivity : Human
Chan LC et al. J Clin Invest 2019; 130 IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion.
Application : WB
Reactivity : Human
Polioudaki H et al. Cell Oncol (Dordr) 2019; (Epub) Nuclear localization of PD-L1: artifact or reality?
Application : WB
Reactivity : Human
Wei-faYang et al. Oral Oncology 2018; 86:81-90 The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Application : IHC-P
Reactivity : Human
Cha JH et al. Mol Cell 2018; 71 (4):606-620.e7 * promotes antitumor immunity via endoplasmic-reticulum-associated degradation of pd-l1.
Application : IHC-Fr
Reactivity : Human
Li CW et al. Cancer Cell 2018; 33 (2):187-201.e10 Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1.
Application : WB
Reactivity : Human
Takeuchi M et al. Immunol Lett 2018; (Epub) Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer.
Application : WB
Reactivity : Human
Liu Z et al. Int J Clin Exp Pathol 2017; 10 (12):11754-11759 Prevalence of programmed death-1 ligand-1 (PD-L1) and infiltrating lymphocytes in human gastric carcinogenesis.
Buisseret L et al. Oncoimmunology 2017; 6 (1):e1257452 Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer.
Liu Z et al. lInt J Clin Exp Pathol 2017; 10 (12):11754-11759 Prevalence of programmed death-1 ligand-1 (PD-L1) and infiltrating lymphocytes in human gastric carcinogenesis.
Application : IHC-P
Reactivity : Human
He B et al. Biomed Pharmacother 2017; 98:95-101 Overexpressed miR-195 attenuated immune escape of diffuse large B-cell lymphoma by targeting PD-L1.
Application : WB
Reactivity : Human
Lin PL et al. Eur J Cancer 2017; 85:95-105 An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
Application : IHC-P
Reactivity : Human
Lin PL et al. Cancer Med 2017; (Epub) A combination of anti-PD-L1 mAb plus Lm-LLO-E6 vaccine efficiently suppresses tumor growth and metastasis in HPV-infected cancers.
Application : IHC-P
Reactivity : Human
Wang LT et al. Cancer Res 2017; (Epub) Intestine-specific homeobox gene ISX integrates interleukin-6 signaling, tryptophan catabolism and immune suppression.
Application : WB
Reactivity : Human
Buisseret L et al. OncoImmunology 2016; (Epub) Tumor Infiltrating Lymphocyte Composition, Organization and PD-1/PD-L1 Expression are Linked in Breast Cancer.
Reactivity : Human
Qing Y et al. Drug Des Devel Ther 2015; 9:901-9 Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer.
Reactivity : Human
Lin YM et al. PLoS One 2015; 10 (11):e0142656 High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma.
Reactivity : Human
SDS
PBS.pdf
Glycerol.pdf
Proclin.pdf
Package List Price ($)
$ 399
$ 169